PhRMA Foundation Announces New Members of Board of Directors - Yahoo Finance

1 year ago 59

, /PRNewswire/ -- The PhRMA Foundation contiguous announced the assignment to its Board of Directors of Aida Habtezion, MD, Chief Medical Officer astatine Pfizer, Maha Radhakrishnan, MD, Chief Medical Officer astatine Biogen, George Addona, PhD, Senior Vice President and Head of Discovery, Preclinical and Translational Medicine astatine Merck Research Laboratories, and Lori Reilly, Esq, Chief Operating Officer astatine PhRMA.

PhRMA Foundation Logo

The PhRMA Foundation is simply a 57-year-old nonprofit that fosters biopharmaceutical innovation and value-driven wellness attraction by investing successful the frontiers of research. The Foundation catalyzes the careers of promising researchers done competitive, peer-reviewed grants and fellowships.

"These caller Board members bring to the PhRMA Foundation a diverseness of acquisition and position that is captious arsenic we participate the adjacent epoch of alteration for the biopharmaceutical industry," said Amy M. Miller, PhD, President of the PhRMA Foundation. "I look guardant to moving with our Board of Directors to illustration a way guardant for the enactment and enactment the rapidly evolving field."

As main aesculapian officer, Dr. Habtezion leads Pfizer's Worldwide Medical & Safety enactment liable for ensuring that patients, physicians, and regulatory agencies are provided with accusation connected the harmless and due usage of Pfizer medications. Prior to joining Pfizer, she was a practicing doc and idiosyncratic astatine Stanford University's School of Medicine, wherever she led a ample translation probe laboratory focused connected knowing illness mechanisms and identifying imaginable immune-based therapeutic targets for pancreatic and intestinal inflammatory diseases and their semipermanent complications specified arsenic cancer.

"As a longtime world researcher who transitioned to industry, I greatly worth the PhRMA Foundation's unsocial relation successful backing promising young scientists conducting probe that helps effect the biopharmaceutical industry's aboriginal efforts to present caller medicines to patients," Dr. Habtezion said. "I americium anxious to spouse with the Foundation's Board and unit to guarantee the continued occurrence of this respected organization."

Biogen's Dr. Radhakrishnan is 1 of the foremost experts connected aesculapian affairs strategy and wellness outcomes probe presently serving arsenic main aesculapian officer. She brings extended acquisition successful overseeing outer engagement approaches with world institutions, cardinal sentiment leaders, diligent advocacy groups, payers, and regulators. Prior to joining Biogen, Dr. Radhakrishnan held enactment roles astatine Sanofi, Bioverativ, Bristol Myers Squibb, United Health Group, and Cephalon.

"By investing successful promising scientists and researchers, the PhRMA Foundation is playing a foundational relation successful helping the biopharmaceutical manufacture accommodate to changing realities," Dr. Radhakrishnan said. "With this evolution, determination are galore challenges the PhRMA Foundation's programs tin assistance the manufacture address. One happening remains wide — we each indispensable travel unneurotic crossed the manufacture to beforehand subject and amended meaningful and measurable diligent outcomes."

Dr. Addona has worked astatine Merck since 2008 and presently oversees early-stage pipeline, aboriginal quality studies, and biomarker development. Previously, helium was Vice President of Quantitative Biosciences, playing a captious relation successful Merck's cause find enactment by starring a multidisciplinary squad focused connected preclinical programs crossed each the company's therapeutic areas. Prior to joining Merck, helium held roles with Novartis and Praecis Pharmaceuticals.

"Our manufacture stands astatine an inflection constituent wherever emerging technologies and caller therapeutic modalities are creating breathtaking opportunities successful medicine and vaccine find and development," Dr. Addona said. "I look guardant to moving with my chap Board members astatine the PhRMA Foundation to foster innovative probe and animate a caller and divers procreation of biopharmaceutical scientists."

Due to a alteration successful the Foundation bylaws, Ms. Reilly joins the Foundation's Board arsenic PhMRA's ex officio representative. A longtime person successful processing and advocating for applicable argumentation solutions that bring medicines to patients, Ms. Reilly oversees PhRMA's advocacy activities and confederation improvement enactment and provides strategical enactment to the enactment and its members. Prior to her 20 years of work astatine PhRMA, she served arsenic counsel to the U.S. House Committee connected Commerce and to a subordinate of the House Ways and Means Committee.

"Research is captious to advancing caller medicines and informing the argumentation situation that paves the mode for patients to entree those medicines," Ms. Reilly said. "The PhRMA Foundation fills a captious niche for the biopharmaceutical industry, helping to substance innovation and physique thoughtful approaches to beforehand a value-driven wellness system."

About the PhRMA Foundation

The PhRMA Foundation fosters biopharmaceutical innovation and value-driven wellness attraction by investing successful the frontiers of research. The Foundation catalyzes the careers of promising researchers done competitive, peer-reviewed grants and fellowships successful the fields of cause delivery, cause discovery, translational medicine, worth appraisal and wellness outcomes research. Since its founding successful 1965, the Foundation has awarded much than $110 million to implicit 2,700 researchers from divers backgrounds astatine much than 300 institutions. To larn more, delight sojourn www.phrmafoundation.org.